Other side effects may include increased hair growth on the face and body, male pattern baldness, change in sex drive, anxiety, depression and pain or inflammation at the injection site.

Males may experience enlargement of the breasts and increase in the frequency and duration of erections.

If any of these effects continue or become bothersome, inform your doctor.

Notify your doctor if you experience nausea, vomiting, swelling of the hands or feet (edema) or jaundice while taking this medication.

In women this may cause menstrual irregularities, hoarseness, deepening of the voice, clitoral enlargement, increased facial hair growth, acne or thinning of hair.

Notify your doctor if any of these effects occur.

Watch the latest videos on YouTube.com

Generic Name: Testosterone Cypionate

Depo-Testosterone 100 mg/ml Vial - Prescription

Testosterone Cypionate 100 mg/ml Vial - Prescription

Andro-Cyp 100 100 mg/ml Vial - Prescription

Depo-Testosterone 200 mg/ml Vial - Prescription

Virilon-IM 200 mg/ml Vial - Prescription

Testosterone Cypionate 200 mg/ml Vial - Prescription

Andro-Cyp 200 200 mg/ml Vial - Prescription

uspi_depo_testosterone

http://www.pfizer.com/download/uspi_depo_testosterone.pdf

testosterone, androgens, injection, patients, testosterone cypionate, male, Depo-Testosterone Injection, dosage, drug, growth, dose, decrease, administration, prostate.

Endogenous androgens are responsible for normal growth and development of the male sex organs and for maintenance of secondary sex characteristics.
About 90 percent of a dose of testosterone is excreted in the urine as glucuronic and sulfuric acid conjugates of testosterone and its metabolites; about 6 percent of a dose is excreted in the feces, mostly in the unconjugated form.
If this occurs, the drug should be discontinued.
If any of these effects appear, the androgen should be stopped and if restarted, a lower dosage should be utilized.
In diabetic patients, the metabolic effects of androgens may decrease blood glucose and, therefore, insulin requirements.

Bulletin98Apr2004

http://formulary.drugplan.health.gov.sk.ca/FormularyBulletins/Bulletin98Apr2004.pdf

tablet, I/C, I/C EDS, ciprofloxacin, INTERCHANGEABLES, ratio-Ciprofloxacin, Exception Drug, Rhoxal-Ciprofloxacin, Citalopram, criteria, pms-Ciprofloxacin, Gen-Ciprofloxacin, Apo-Ciproflox, Novo-Ciprofloxacin.

This Bulletin is not to be reproduced or republished except with the approval of the Saskatchewan Formulary Committee.
Inquiries should be directed to the address shown at left.
amoxicillin trihydrate/potassium clavulanate, tablet, 875/125 mg (Novo-Clavamoxin-NOP) New interchangeable - same criteria as other brand listed in Appendix A, page 219.
meloxicam, tablet, 7.5mg, 15mg (ratio-Meloxicam-RPH) New interchangeable - same criteria as other brand listed in Appendix A, page 237.
ofloxacin, ophthalmic solution, 0.3% ophthalmic solution (Apo-Ofloxacin-APX) New interchangeable - same criteria as other brand listed in Appendix A, page 240.

03-9065

http://www.fda.gov/OHRMS/DOCKETS/98fr/03-9065.pdf

estrogens, drug, drug products, effectiveness, menopause, estrogen alone, FDA, patients, androgens, administration, ANDA, withdrawn, substantial evidence, request.

17, 1998 (63 FR 69631), FDA withdrew approval of estrogen-containing drugs insofar as they are indicated for postpartum breast engorgement because estrogens have not been shown to be safe for this use.
This action was taken as one part of a large agency undertaking with respect to the labeling (patient-directed as well as physician-directed) for all estrogencontaining drug products.
3. Kaunitz, A. M., ''The Role of Androgens in Menopausal Hormonal Replacement,'' Endocrinology and Metabolism Clinics of North America, 26(2):391--397, 1997.
Notice of Opportunity for a Hearing Any manufacturer or distributor of a drug product affected by this notice is hereby offered an opportunity for a hearing to show why estrogen-androgen combination drugs should not be reclassified as lacking substantial evidence of effectiveness for moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogen alone.